AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01547455
Drug: Atorvastatin(Lipitor)
RxNorm normalized name: atorvastatin Oral Tablet [Lipitor]
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
Trial: NCT00978211
Drug: DOTA-TOC Treatment
RxNorm normalized name: DOTA-TATE
DrugBank: Edotreotide (DB17969)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of~* renal toxicity~* loss of patient transferability or~* denial of further treatment.
Trial: NCT03711578
Drug: Tenalisib,
DrugBank: Tenalisib (DB15295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID, Orally
Trial: NCT00999531
Drug: GS-9411
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inhaled GS-9411 dissolved in sterile saline
Trial: NCT03473574
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: standard chemotherapy
Trial: NCT03473574
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard chemotherapy
Trial: NCT00000421
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00526513
Drug: Insulin Glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: subcutaneous injection of insulin glulisine at meal, 1 to 3 injections a day based on the condition of the patient in addition to a basal SC insulin injection at bedtime
Trial: NCT01976338
Drug: Ranibizumab 0.5 mg
RxNorm normalized name: ranibizumab 0.5 MG in 0.05 ML Injection
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal injection of 0.05 ml
Trial: NCT02595450
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
Trial: NCT00698243
Drug: OSI-027
RxNorm normalized name: OSI-027
DrugBank: OSI-027 (DB12387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01655914
Drug: Flumazenil
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01448486
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral raltegravir, 400 mg tablet, twice daily for one year.
Trial: NCT01934556
Drug: Ranibizumab 0.3 mg intravitreal injection
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00777608
Drug: Donepezil 5 - 10 mg
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil 1 capsule (5 mg) orally, once daily for 14 days.~Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84).
Trial: NCT00777608
Drug: Donepezil 10 mg
RxNorm normalized name: donepezil 10 mg oral tablet
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
Trial: NCT03148132
Drug: Bevacizumab Injection
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5mg/0.02 mL
Trial: NCT03148132
Drug: Ranibizumab Ophthalmic
RxNorm normalized name: ranibizumab ophthalmic
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.25mg/0.025 mL
Trial: NCT00934830
Drug: Antibiotic (Amoxicillin)
RxNorm normalized name: Amoxicillin
DrugBank: Gramicidin D (DB00027)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg, 3 times per day for 10 days
Trial: NCT03247972
Drug: Evolocumab
RxNorm normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sixty subjects will be treated with high dose statins for 8 weeks followed by 8 weeks of high dose statin + evolocumab (420mg/4 wk) therapy.
Trial: NCT01383486
Drug: Advil
RxNorm normalized name: Advil
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Commercially available Advil; oral caplet upon incidence of pain
Trial: NCT00655590
Drug: Levitra (Vardenafil, BAY38-9456)
RxNorm normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg daily dosing
Trial: NCT00655590
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg daily dosing
Trial: NCT01010932
Drug: Dotarem
RxNorm normalized name: Dotarem
DrugBank: Gadoteric acid (DB09132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive one injection of Dotarem 0.2ml/kg
Trial: NCT02115347
Drug: Ertugliflozin 15 mg
RxNorm normalized name: ertugliflozin 15 MG
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet
Trial: NCT03600467
Drug: SEVI-D (Seviteronel in combination with dexamthasone)
RxNorm normalized name: aminophenazone, combinations with psycholeptics
DrugBank: Aminophenazone (DB01424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of SEVI-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.~Serivteronel will be administered orally at 450 mg (3 tables) once daily. It will be given in combination with one oral tablet of 0.5 mg tablet of Dexamethosone. SEVI-D will be continuously administered daily while on the study.~Clinical and safety assessments are scheduled every 4 weeks during the study and then every 8 weeks after the end of the safety follow up period of the study.
Trial: NCT02297763
Drug: quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient body weight \<50kg : quetiapine 12.5mg patient body weight \>=50kg : quetiapine 25mg~quetiapine 12.5mg (bwt \<50kg ) or 25mg (bwt\>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.~The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water).
Trial: NCT01307215
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mLs of 0.5%
Trial: NCT01307215
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mLs of 0.33%
Trial: NCT01986491
Drug: JNJ 39393406 30 mg solid X
RxNorm normalized name: JNJ-39393406
DrugBank: JNJ-39393406 (DB11867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).
Trial: NCT01986491
Drug: JNJ 39393406 120 mg solid X
RxNorm normalized name: JNJ-39393406
DrugBank: JNJ-39393406 (DB11867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).
Trial: NCT01307215
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mLs of 0.25%
Trial: NCT01986491
Drug: JNJ 39393406 30 mg solution
RxNorm normalized name: JNJ-39393406
DrugBank: JNJ-39393406 (DB11867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).
Trial: NCT01471886
Drug: Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every 8 hours for 4 days.
Trial: NCT00274027
Drug: tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02580279
Drug: EGCG
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03891784
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03829930
Drug: Entinostat
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat is formulated for oral administration. A food effect is evident for entinostat; exposure is significantly reduced when entinostat is administered with a high fat meal. Accordingly, entinostat is to be administered on an empty stomach, at least 1 hour before and 2 hours after a meal. Entinostat tablets should not be split, crushed, or chewed. Consult the individual clinical protocols for specific dosing instructions.~Dose level 1: 3mg PO weekly. Dose level 2: 5mg PO weekly.
Trial: NCT03829930
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose level 1: 160 mg PO daily. Dose level 2: 160 mg PO daily.
Trial: NCT01188889
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib will be given continuously at a fixed daily dose of 400 mg once daily.
Trial: NCT00834340
Drug: Glimepiride 4 mg Tablets
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 4 mg, single-dose fasting
Trial: NCT03620591
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative administration of lidocaine
Trial: NCT01258504
Drug: St. Johns Wort
RxNorm normalized name: St. johns wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19.~* Administration of SJW: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20
Trial: NCT00705211
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe, 10-mg tablets,
Trial: NCT00705211
Drug: Ezetimibe + other lipid-lowering medication(s)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe, 10-mg tablets, other lipid-lowering medication(s) as prescribed by attending physician
Trial: NCT01531920
Drug: alcohol + perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part A: alcohol + perampanel
Trial: NCT01531920
Drug: perampanel + alcohol
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part B: perampanel + alcohol
Trial: NCT01066364
Drug: Colesevelam Hcl
RxNorm normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3.75 gm/day (six 675 mg tablets)
Trial: NCT03574090
Drug: Amoxicillin Clavulanate
RxNorm normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
Trial: NCT03451773
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard (1,000 mg/m\^2) or reduced (600 mg/m\^2 for 4 doses) intravenous (IV) once a week for first 4 weeks. Then, once weekly for 3 weeks with one week rest. Gemcitabine will be discontinued after 6 months of therapy
Trial: NCT00308152
Drug: Infusion of 1 litre of normal saline before colonoscopy
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehydration with normal saline
Trial: NCT00235352
Drug: CX516 (Ampakine)
RxNorm normalized name: CX516
DrugBank: CX516 (DB06247)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00528788
Drug: doxercalciferol
RxNorm normalized name: Doxercalciferol
DrugBank: Doxercalciferol (DB06410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02469753
Drug: NSAIDs
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous daily
Trial: NCT01617460
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Flexibly dose administered orally once daily
Trial: NCT01140360
Drug: Gleevec
RxNorm normalized name: Gleevec
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA \> 1.8 m2 or 55 mg/m2 twice daily for patients with BSA \< 1.8 m2. For patients with a BSA \> 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA \< 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
Trial: NCT01491919
Drug: Lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to Low, Medium, or High dose of Lisinopril
Trial: NCT02469753
Drug: NSAIDs
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: on demand
Trial: NCT04467424
Drug: ketamine, propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anesthesia with ketofol in pediatric surgery
Trial: NCT04467424
Drug: ketamine, propofol, lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anesthesia with ketofol plus lidocaine in pediatric surgery
Trial: NCT02951715
Drug: zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day)
Trial: NCT01566773
Drug: PT001 MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as two puffs BID for 14 days
Trial: NCT01566773
Drug: Tiotropium Bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI
Trial: NCT00390546
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00390546
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00762892
Drug: Raltegravir and truvada
RxNorm normalized name: Truvada
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Raltegravir 400 mg po bid, truvada 1 tab q daily
Trial: NCT00762892
Drug: Atazanavir, Norvir and Truvada
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily
Trial: NCT00670319
Drug: Raloxifene HCL
RxNorm normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene HCL 60 mg orally once daily
Trial: NCT00670319
Drug: Raloxifene HCL
RxNorm normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene HCL 120 mg orally once daily
Trial: NCT04369937
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between programmed cell death protein 1 (PD-1) and its ligands, PD-L1 and PD-L2.
Trial: NCT04369937
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT03265574
Drug: Enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril is an Angiotensin Converting Enzyme (ACE) inhibitor which supresses the reninangiotensin-aldosterone system resulting in increased plasma renin activity and decreased aldosterone secretion
Trial: NCT02294786
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lapatinib was supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contained 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base
Trial: NCT02294786
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections were given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol was added to the microspheres to improve suspendability
Trial: NCT00571064
Drug: Donepezil HCl
RxNorm normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.
Trial: NCT00784420
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Raltegravir 400 mg twice daily for 10 days
Trial: NCT01773109
Drug: Etirinotecan pegol (NKTR-102)
RxNorm normalized name: Certolizumab Pegol
DrugBank: Etirinotecan pegol (DB14951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Treatment will be administered on an outpatient basis.
Trial: NCT02812121
Drug: umbilical cord blood mesenchymal stem cells
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01033734
Drug: oseltamivir [Tamiflu]
DrugBank: Oseltamivir acid (DB02600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
Trial: NCT02614586
Drug: TAK-058
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-058 oral solution.
Trial: NCT02614586
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron capsule.
Trial: NCT02614586
Drug: Ondansetron Placebo
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron placebo-matching, capsule.
Trial: NCT00520936
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1910 milligrams per meter squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old), intravenous (IV), for 21 days x 17 cycles
Trial: NCT03080298
Drug: BP101
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01996293
Drug: lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine will be observed in women who have already under the guidance of a physician decide to continue lamotrigine for the treatment of Bipolar Disorder
Trial: NCT03025477
Drug: CC0 - Carboplatin (IV) - Paclitaxel (IV)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (6 cycles)
Trial: NCT03025477
Drug: CC0 - Cisplatin (IP) - Epirubicin (IV)
RxNorm normalized name: Cisplatin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (6 cycles)
Trial: NCT03025477
Drug: CC>0 - Carboplatin (IV)- Paclitaxel (IV)
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * carboplatin (IV) - paclitaxel (IV) (3 cycles)~* Interval surgery~* Carboplatin (IV) - paclitaxel (IV) (3 cycles)
Trial: NCT03025477
Drug: CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Cisplatin (IV) - Epirubicin (IV) (3 cycles)~* Interval surgery :~  * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)~ * if CC\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)
Trial: NCT02197637
Drug: ORAL VINORELBINE
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle If on D8 and D15, the administration conditions are not met, the administration is canceled and not delayed.